小剂量替罗非班治疗急性缺血性脑卒中溶栓后早期神经功能恶化的效果

摘要
图/表
参考文献
相关文章 (3)

全文: PDF (1036 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨小剂量替罗非班对急性缺血性脑卒中(Acute Ischemic Stroke,AIS)静脉溶栓(Intravenous Thrombolysis,IVT)后早期神经功能恶化(Early Neurological Deterioration,END)的预防效果及安全性。方法 2017年7月—2019年9月在某院接受阿替普酶静脉溶栓的AIS患者144例,溶栓后1 h复查头颅CT,观察未发现存在颅内出血者根据患者及家属意愿决定是否使用替罗非班抗血小板治疗,据此分为观察组和对照组;比较2组患者基线资料,END、症状性颅内出血(Symptomatic Intracerebral Hemorrhage,sICH)、系统性出血发生率及死亡率;评估2组患者IVT后3个月预后情况。结果观察组END发生率为7.87%,对照组为20.00%,差异具有统计学意义(χ2=4.576,P=0.032);观察组发生sICH、系统性出血及死亡率与对照组比较差异均无统计学意义(P均＞0.05);静脉溶栓后24 h ,85.39%(76/89)的观察组患者出现CPI,对照组有70.91%(39/55),差异具有统计学意义(χ2=4.434,P=0.035);观察组有2例出现DFI,对照组有9例出现DFI,差异具有统计学意义(χ2=9.601,P=0.002);静脉溶栓3个月后,观察组预后良好率为70.79%,对照组为52.73%,差异具有统计学意义(χ2=4.805,P=0.028)。结论静脉溶栓后早期联合小剂量替罗非班治疗AIS是安全有效的,能够显著降低早期神经功能恶化程度,短期预后良好。　

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孙锋
	李会晓
	崔炎增

关键词 ：急性缺血性脑卒中, 静脉溶栓, 替罗非班, 临床结局

Abstract：Objective To investigate the preventive effect and safety of low-dose tirofiban in early neurological deterioration (END) after acute ischemic stroke (AIS) intravenous thrombolysis (IVT). Methods From July 2017 to September 2019, 144 patients with AIS who received intravenous thrombolysis with alteplase in a hospital, and no intracranial hemorrhage was found after re-examination of head CT 1 h after thrombolysis and then decided whether to use tirofiban antiplatelet therapy according to the wishes of patients and their families, which were divided into an observation group and a control group. The baseline data, END, symptomatic intracerebral hemorrhage (sICH), the incidence of systemic bleeding, and mortality were compared between the two groups. The prognoses of patients in both groups at 3 months after IVT were assessed. Results The incidence of END in the observation group was 7.87% and 20.00% in the control group, and the difference was statistically significant (χ2=4.576, P=0.032). There were no significant differences in sICH, systemic bleeding, and mortality between the observation group and the control group (all P>0.05). CPI was present in 85.39% (76/89) of patients in the observation group 24 hours after intravenous thrombolysis, and 70.91% (39/55) in the control group, and the difference between the two groups was statistically significant (χ2=4.434, P=0.035). DFI occurred in 2 cases in the observation group and 9 cases in the control group, and the difference was statistically significant (χ2=9.601, P=0.002). After 3 months of intravenous thrombolysis, the good prognosis rate was 70.79% in the observation group and 52.73% in the control group, and the difference was statistically significant (χ2=4.805, P=0.028). Conclusion The early combination of intravenous thrombolysis combined with low-dose tirofiban in the treatment of AIS is safe and effective, which can significantly reduce the deterioration of early neurological function, and the short-term prognosis is good.

Key words： Acute ischemic stroke (AIS) Intravenous thrombolysis (IVT) Tirofiban Clinical outcome

收稿日期: 2023-02-20

ZTFLH:

R453

作者简介: 孙锋(1989—),男,河南商丘人,主治医师,本科学历,主要从事神经内科重症监护工作。

引用本文:

孙锋,李会晓,崔炎增. 小剂量替罗非班治疗急性缺血性脑卒中溶栓后早期神经功能恶化的效果[J]. 中国校医, 2024, 38(1): 54-57.
SUN Feng, LI Huixiao, CUI Yanzeng. Effect of low-dose tirofiban in treatment of early neurological deterioration after thrombolysis in acute ischemic stroke. Chinese Journal of School Doctor, 2024, 38(1): 54-57.

链接本文:

https://www.zgxyzz.org.cn/CN/ 或 https://www.zgxyzz.org.cn/CN/Y2024/V38/I1/54

[1] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[2] Cheng Z,Geng X,Gao J,et al. Intravenous administration ofstandard dose tirofiban after mechanical arterial recanalization issafe and relatively effective in acute ischemic stroke[J]. AgingDis,2019,10(5):1049-1057.
[3] 山媛,崔小丽,蒋锋,等.血小板膜糖蛋白Ⅱb、Ⅲa基因多态性与急性缺血性脑卒中的关系研究[J].实用心脑肺血管病杂志,2019,27(3):35-39.
[4] Wu C,Sun C,Wang L,et al. Low-dose tirofiban treatment improvesneurological deterioration outcome after intravenous thrombolysis.stroke,2019,50(12):3481-3487.
[5] 王军,王德昭.高剂量替罗非班在急性ST段抬高型心肌梗死患者直接经皮冠状动脉介入术中的安全性及有效性评价[J].中国全科医学,2015(27):3276-3283.
[6] Yu T,Lin Y,Jin A,et al. Safety and efficiency of low dose intra-arterial tirofiban in mechanical thrombectomy during acute ischemicstroke[J]. Curr Neurovasc Res,2018,15(2):145-150.
[7] 马兆雷,毛诗贤,王伟,等.用HAT评分评估急性缺血性脑卒中静脉溶栓后出血转化的风险[C].中华医学会第十八次全国神经病学学术会议,2015.
[8] 李瑞英,陈会生.急性缺血性脑卒中早期神经功能恶化研究现状及进展[J].临床军医杂志,2017,45(2):136-139.
[9] 杨绍婉,梁志刚,于国平,等.缺血性卒中静脉溶栓后有症状颅内出血:预测和治疗[J].国际脑血管病杂志,2018,26(3):201-206.
[10] Liu J,Shi Q,Sun Y,et al. Efficacy of Tirofiban administered atdifferent time points after intravenous thrombolytic therapy withalteplase in patients with acute ischemicstroke[J]. J Stroke Cereb-rovasc Dis,2019,28(4):1126-1132.
[11] Niu J,Ding Y,Zhai T,et al. The efficacy and safety of tirofiban forpatients with acute ischemic stroke:a protocol for systematic reviewand a meta-analysis[J]. Medicine(Baltimore),2019,98(9):e14673.
[12] 王欢,李玮,刘承春,等.脑梗死静脉溶栓后24 h内选择性双联抗血小板治疗的安全性观察[J].中国卒中杂志,2014(10):831-836.
[13] 高擎,刘春梅.急性大血管闭塞性卒中静脉溶栓桥接机械取栓中应用替罗非班的疗效及安全性分析[J].徐州医科大学学报,2019,39(8):551-556.
[14] 刘华为,叶峰.阿替普酶静脉溶栓联合抗血小板治疗对急性缺血性轻型脑卒中患者心脑血管不良事件再发的影响[J].中国基层医药,2019,26(4):461-465.
[15] Luo Y,AUID-Oho,Yang Y,et al. Therapeutic effect of pre-operative tirofiban on patients with acute ischemic stroke withmechanical thrombectomy within 6-24 hours[J].Interv Neuroradiol,2019,25(6):705-709.
[16] Zhao W,Che R,Shang S,et al. Low-dose Tirofiban improvesfunctional outcome in acute ischemic stroke patients treated withendovascular thrombectomy[J].Stroke,2017,48(12):3289-3294.
[17] 林露.替罗非班治疗急性缺血性卒中的安全性与有效性研究[D].重庆:中国人民解放军第三军医大学,2017.